Kairos Pharma, LTD.
Kairos Pharma develops novel therapies to combat cancer drug resistance and restore immune response, advancing innovative treatments for cancer patients.
Funding history
About Kairos Pharma, LTD.
How much funding has Kairos Pharma, LTD. raised?
Kairos Pharma, LTD. has raised $3.5M in total funding.
Where is Kairos Pharma, LTD. headquartered?
Kairos Pharma, LTD. is headquartered in Los Angeles, CA.
What does Kairos Pharma, LTD. do?
Kairos Pharma develops novel therapies to combat cancer drug resistance and restore immune response, advancing innovative treatments for cancer patients.
What problem does Kairos Pharma, LTD. solve?
Cancer drugs often stop working over time as tumors develop resistance and cancer cells suppress the immune system's T-cell response.
What's Kairos Pharma, LTD.'s solution?
Kairos Pharma develops therapeutics, including its lead antibody ENV105, designed to reverse cancer drug resistance and reverse cancer-induced immune suppression so existing treatments become effective again.
What makes Kairos Pharma, LTD. different?
The page claims Kairos discovered that cancer cells produce a protein called CD105 as the central mechanism driving resistance to drugs like Xtandi, Zytiga, Tagrisso, and others, and that ENV105 (which targets CD105) is already in Phase 2 (prostate) and Phase 1 (lung) trials with a cleared IND in glioblastoma and IP protection through 2040.
What makes Kairos Pharma, LTD. notable?
Kairos Pharma's CEO and Chairman, John S. Yu, MD, is a Cedars-Sinai Medical Center neurosurgery professor and Medical Director of its Brain Tumor Center; the company trades publicly on NYSE American under ticker KAPA.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.